Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT07622706 2026-06-03

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Phase 2 Not yet recruiting

60 enrolled

Thoracic

NSCLC

NCT07185997 2026-05-11

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Phase 3 Recruiting

480 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT07548060 2026-04-23

TROP-LUNG

Phase 2 Recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07517640 2026-04-08

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Phase 2 Not yet recruiting

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Completed

46 enrolled

CNS

Meningeal Carcinomatosis

NCT07348965 2026-04-02

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Phase NA Recruiting

42 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Phase 1 Recruiting

288 enrolled

Thoracic

Advanced Non-small Cell Lung Cancer

NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Phase 2 Not yet recruiting

63 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

NCT05364073 2026-03-13

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Phase 1 Active not recruiting

160 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

TROP-LUNG

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations